PR Newswire • 18 days agoAmarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm™") in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG") for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. Amarantus' wholly-owned subsidiary Cutanogen Corporation is pursuing the development of ESS towards regulatory approval for the treatment of life-threatening severe burns.
Banks are offering insane credit card deals if you have great credit. Take advantage of double cash back, a $625 intro bonus, 0% interest until 2018.
GlobeNewswire • 2 months agoAvant Diagnostics Presented Data on TheraLink® Pancreatic Cancer Assay at the International Symposium on Pancreas Cancer 2016
SCOTTSDALE, Ariz. and GAITHERSBERG, Md., June 14, 2016-- Avant Diagnostics, Inc., an innovative molecular diagnostics company, today announced that Dr. Vince Picozzi presented data on use of the Company’ ...
Amarantus Bioscience Holdings, Inc (AMBS)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.05 - 0.06|
|52wk Range||0.03 - 2.70|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-0.02|
|Avg Vol (3m)||481,184|
|Dividend & Yield||N/A (N/A)|